Nuvalent reported that the U.S. Food and Drug Administration granted breakthrough therapy designation to NVL-655 for (ALK)-positive non-small cell lung cancer

On May 16, 2024, Nuvalent, Inc. reported that the U.S. Food and Drug Administration granted breakthrough therapy designation to NVL-655 for the treatment of patients with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who have been previously treated with two or more ALK tyrosine kinase inhibitors (Press release, Nuvalent, MAY 16, 2024, View Source [SID1234643401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!